Lymphoblastic Lymphoma: Epidemio-Clinical, Therapeutic and Prognostic Aspects

Abstract

Lymphoblastic lymphoma (LL) is a multifactorial, frequent and highly progressive but curable cancer, and one of the haemopathies frequently managed at the Mohammed VI University Hospital, Marrakech. Seventeen patients with lymphoblastic lymphoma (LL) were included in this study. The annual hospital incidence of LL in Marrakech was 1.8 cases/year. The 6-10 age group was in the majority (n=11; 70%). The sex ratio was 3.25 in favor of boys, and 82% had RAMED, which corresponds to a low socioeconomic level. Dyspnea was found in 10 patients (60%). Stage 3 was in the majority (n=7; 70%). Diagnosis was made by cytology in 94% of patients, histology in 23% and immunohistochemistry in 82%. Four patients died of chemotherapy toxicity after blood product rupture, and 3 of disease progression on chemotherapy. The 10 patients in remission survived event-free for an average of 21 months.